Literature DB >> 16714375

Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules.

Femke M van de Water1, Otto C Boerman, Alfons C Wouterse, Janny G P Peters, Frans G M Russel, Rosalinde Masereeuw.   

Abstract

Different gene-silencing methods, like antisense and short interfering RNA (siRNA), are widely used as experimental tools to inhibit gene expression. In the present study, the in vivo behavior of siRNA in rats and siRNA-mediated silencing of genes in the renal proximal tubule were investigated. To study the biodistribution of siRNA, rats were injected i.v. with radiolabeled siRNA or radiolabel alone (control), and scintigraphic images were acquired at different time intervals postinjection. The siRNA preferentially accumulated in the kidneys and was excreted in the urine. One hour after injection, the amount of siRNA present in both kidneys (1.7 +/- 0.3% of injected dose/g tissue) was on average 40 times higher than in other tissues (liver, brain, intestine, muscle, lung, spleen, and blood). Besides the biodistribution, the effect of siRNA on multidrug resistance protein isoform 2 (Mrp2/Abcc2, siRNAMrp2) in renal proximal tubules was investigated. Mrp2 function was assessed by measuring the excretion of its fluorescent substrate calcein in the isolated perfused rat kidney. Four days after administration, siRNAMrp2 reduced the urinary calcein excretion rate significantly (35% inhibition over the period 80-150 min of perfusion). This down-regulation was specific because another siRNA sequence directed against a different transporter in the proximal tubule, Mrp4 (Abcc4, siRNAMrp4), did not alter the Mrp2-mediated excretion of calcein. In conclusion, siRNA accumulates spontaneously in the kidney after i.v. injection, where it selectively suppresses gene function in the proximal tubules. Therefore, i.v. administered siRNA provides a novel experimental and potential therapeutic tool for gene silencing in the kidney.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714375     DOI: 10.1124/dmd.106.009555

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  66 in total

Review 1.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

2.  Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.

Authors:  Jie Wang; Ze Lu; Junfeng Wang; Minjian Cui; Bertrand Z Yeung; David J Cole; M Guillaume Wientjes; Jessie L-S Au
Journal:  J Control Release       Date:  2015-08-10       Impact factor: 9.776

Review 3.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

Review 4.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

Authors:  Shan Gao; Frederik Dagnaes-Hansen; Ebbe Juel Bech Nielsen; Jesper Wengel; Flemming Besenbacher; Kenneth Alan Howard; Jørgen Kjems
Journal:  Mol Ther       Date:  2009-04-28       Impact factor: 11.454

Review 6.  New short interfering RNA-based therapies for glomerulonephritis.

Authors:  Hideki Shimizu; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

7.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.

Authors:  Derek W Bartlett; Helen Su; Isabel J Hildebrandt; Wolfgang A Weber; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

8.  Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation.

Authors:  Daqing Ma; Ta Lim; Jing Xu; Haidy Tang; Yanjie Wan; Hailin Zhao; Mahmuda Hossain; Patrick H Maxwell; Mervyn Maze
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

9.  Zag expression during aging suppresses proliferation after kidney injury.

Authors:  Roland Schmitt; Arnaud Marlier; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2008-09-24       Impact factor: 10.121

10.  Establishment of a positive-readout reporter system for siRNAs.

Authors:  Wei-Li Liu; Douglas P Owen; Kerry D Fisher; Leonard W Seymour; Mark Stevenson
Journal:  J RNAi Gene Silencing       Date:  2009-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.